Federated Hermes, Inc. Alnylam Pharmaceuticals, Inc. Transaction History

Federated Hermes, Inc.

$43.6 Billion
Q3 2024

A detailed history of Federated Hermes, Inc. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 168,923 shares of ALNY stock, worth $41.1 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares

168,923

Previous 92,608 82.41%

Holding current value

$41.1 Million

Previous $22.5 Million 106.49%

% of portfolio

0.11%

Previous 0.05%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$233.81 - $287.01 $17.8 Million - $21.9 Million	76,315 Added 82.41%	168,923 $46.5 Million
Q2 2024 Aug 08, 2024	SELL	$143.31 - $247.0 $8.01 Million - $13.8 Million	-55,896 Reduced 37.64%	92,608 $22.5 Million
Q1 2024 May 14, 2024	BUY	$146.51 - $198.2 $1.66 Million - $2.25 Million	11,363 Added 8.29%	148,504 $22.2 Million
Q4 2023 Jan 31, 2024	BUY	$151.41 - $196.57 $20.8 Million - $27 Million	137,141 New	137,141 $26.3 Million
Q2 2023 Aug 14, 2023	SELL	$185.01 - $212.05 $7.82 Million - $8.96 Million	-42,245 Reduced 91.23%	4,060 $771,000
Q1 2023 May 08, 2023	SELL	$182.66 - $235.53 $146,858 - $189,366	-804 Reduced 1.71%	46,305 $9.28 Million
Q4 2022 Feb 13, 2023	BUY	$185.53 - $241.31 $8.74 Million - $11.4 Million	47,109 New	47,109 $11.2 Million
Q1 2022 May 13, 2022	SELL	$127.18 - $173.91 $126 Million - $173 Million	-992,180 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$159.56 - $209.29 $5.32 Million - $6.98 Million	33,360 Added 3.48%	992,180 $168 Million
Q3 2021 Nov 15, 2021	SELL	$169.75 - $207.73 $3.95 Million - $4.83 Million	-23,258 Reduced 2.37%	958,820 $181 Million
Q2 2021 Aug 16, 2021	SELL	$128.63 - $176.89 $854,103 - $1.17 Million	-6,640 Reduced 0.67%	982,078 $166 Million
Q1 2021 May 13, 2021	BUY	$126.83 - $175.69 $32.1 Million - $44.5 Million	253,244 Added 34.43%	988,718 $140 Million
Q4 2020 Feb 12, 2021	BUY	$122.97 - $147.0 $21.2 Million - $25.4 Million	172,563 Added 30.66%	735,474 $95.6 Million
Q3 2020 Nov 12, 2020	SELL	$121.19 - $165.49 $1.64 Million - $2.24 Million	-13,558 Reduced 2.35%	562,911 $82 Million
Q2 2020 Aug 13, 2020	SELL	$104.21 - $156.44 $1.62 Million - $2.43 Million	-15,547 Reduced 2.63%	576,469 $85.4 Million
Q1 2020 May 13, 2020	SELL	$93.12 - $133.99 $13.3 Million - $19.1 Million	-142,346 Reduced 19.38%	592,016 $64.4 Million
Q4 2019 Feb 14, 2020	BUY	$74.51 - $124.23 $13.3 Million - $22.2 Million	178,973 Added 32.22%	734,362 $84.6 Million
Q3 2019 Nov 14, 2019	BUY	$70.9 - $87.82 $6.26 Million - $7.75 Million	88,240 Added 18.89%	555,389 $44.7 Million
Q2 2019 Aug 14, 2019	SELL	$65.86 - $92.79 $3.95 Million - $5.57 Million	-60,002 Reduced 11.38%	467,149 $33.9 Million
Q1 2019 May 10, 2019	BUY	$72.76 - $93.45 $65,484 - $84,105	900 Added 0.17%	527,151 $49.3 Million
Q4 2018 Feb 13, 2019	SELL	$62.67 - $88.33 $7.84 Million - $11.1 Million	-125,116 Reduced 19.21%	526,251 $38.4 Million
Q3 2018 Nov 13, 2018	BUY	$87.52 - $122.67 $4.21 Million - $5.9 Million	48,117 Added 7.98%	651,367 $57 Million
Q2 2018 Aug 10, 2018	BUY	$88.31 - $107.8 $17.9 Million - $21.8 Million	202,207 Added 50.42%	603,250 $59.4 Million
Q1 2018 May 09, 2018	SELL	$115.92 - $148.54 $26.4 Million - $33.9 Million	-228,037 Reduced 36.25%	401,043 $47.8 Million
Q4 2017 Feb 14, 2018	BUY	$114.49 - $139.98 $52.4 Million - $64.1 Million	457,913 Added 267.52%	629,080 $0
Q3 2017 Nov 13, 2017	BUY	$72.53 - $118.27 $12.4 Million - $20.2 Million	171,167	171,167 $20.1 Million

Others Institutions Holding ALNY

# of Institutions

643

Shares Held

109M

Call Options Held

1.28M

Put Options Held

1.21M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $29.9B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.

Account

Federated Hermes, Inc. Alnylam Pharmaceuticals, Inc. Transaction History